TB006
TB006 is a pharmaceutical drug with 8 clinical trials. Currently 2 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
40.0%
2 of 5 finished
60.0%
3 ended early
2
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
TB006 for Autism Spectrum Disorder
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
TB006 Expanded Access (EA) Compassionate Use
Clinical Trials (8)
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
TB006 for Autism Spectrum Disorder
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
TB006 Expanded Access (EA) Compassionate Use
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8